EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis

Eleonora Castellana, Patricia Madalina Budau, Cecilia Miglietta, Paola Milla, Maria Rachele Chiappetta

Therapeutic Innovation & Regulatory Science · 2026

DOI: 10.1007/s43441-026-00966-4 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2026. Verfasst von Eleonora Castellana und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Pharmacy, University Hospital Città della Salute e della Scienza of Turin, Turin, Piedmont, Italy. Hauptthemen laut MEDLINE: Antineoplastic Agents, Chylothorax, Dasatinib, Protein Kinase Inhibitors. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Torino.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dasatinib, a second-generation tyrosine kinase inhibitor widely used for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL), has been reported in association with rare cases of chylothorax.

Objective

To systematically summarize published case reports and complement these findings with pharmacovigilance data in order to characterize the clinical presentation, management, and outcomes of dasatinib-associated chylothorax.

Methods

A scoping review was conducted in accordance with PRISMA 2020 recommendations. PubMed/MEDLINE and an institutional discovery platform were searched for case reports and case series published up to February 13, 2026. Eligible reports included patients developing chylothorax during dasatinib therapy. In parallel, data from the FDA Adverse Event Reporting System (FAERS) were analyzed through September 30, 2024. Descriptive analyses were performed. FAERS data were interpreted as hypothesis-generating only.

Results

Forty-two publications describing 44 patients met the inclusion criteria. Patients ranged from 5 to 90 years of age, with a slight male predominance. Time from dasatinib initiation to chylothorax onset varied from 2 months to 10 years. Management most commonly involved drug discontinuation and thoracentesis, frequently followed by clinical resolution. FAERS analysis identified 104 unique reports of chylothorax associated with dasatinib, all classified as serious adverse events; severe outcomes were uncommon. Reporting trends increased over time, particularly between 2017 and 2023.

Limitations

Evidence derives from case reports and spontaneous reporting data, which do not allow estimation of incidence or causal inference and are subject to reporting bias and incomplete information.

Conclusions

Dasatinib-associated chylothorax is an uncommon but clinically relevant event that may occur even after prolonged therapy. Long-term monitoring and prompt recognition are essential. Findings from pharmacovigilance data should be interpreted cautiously and considered hypothesis-generating. Further studies using large retrospective administrative databases are warranted to formally evaluate this potential association.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsChylothoraxDasatinibProtein Kinase InhibitorsAdolescentAdultAgedAged, 80 and overChildFemaleHumansMaleMiddle AgedAdverse Drug Reaction Reporting SystemsPharmacovigilance

Stichwörter der Autor:innen

BCR-ABL positiveChronicChylothoraxDasatinibDrug-related side effects and adverse reactionsLeukemiaMyelogenousPharmacovigilanceSpontaneous reporting systems

Substanzen

Antineoplastic AgentsDasatinibProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Hospital Pharmacy, University Hospital Città della Salute e della Scienza of Turin, Turin, Piedmont, Italy.
  • Hospital Pharmacy, University Hospital Città della Salute e della Scienza of Turin, Turin, Piedmont, Italy. patriciamadalina.budau@unito.it.
  • Università degli Studi di Torino, Turin, Italy. patriciamadalina.budau@unito.it.
  • School of Specialization in Hospital Pharmacy, University of Turin, Turin, Piedmont, Italy. patriciamadalina.budau@unito.it.
  • School of Specialization in Hospital Pharmacy, University of Turin, Turin, Piedmont, Italy.
  • Department of Drug Science and Technology, University of Turin, Turin, Piedmont, Italy.

Förderung

  • Università degli Studi di Torino

Zitieren

APA

Castellana, E., Budau, P. M., Miglietta, C., Milla, P., & Chiappetta, M. R. (2026). Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-026-00966-4

Vancouver

Castellana E, Budau PM, Miglietta C, Milla P, Chiappetta MR. Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis. Therapeutic Innovation & Regulatory Science. 2026. doi:10.1007/s43441-026-00966-4

BibTeX
@article{Castellana2026,
  author = {Castellana, Eleonora and Budau, Patricia Madalina and Miglietta, Cecilia and Milla, Paola and Chiappetta, Maria Rachele},
  title = {Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  doi = {10.1007/s43441-026-00966-4}
}
Kostenlos starten →